The FDA’s decision last year to make complete response letters public provides new insight into why therapies sometimes fail to get the regulatory greenlight. Analysts say...
Merck, Amgen double down on bad cholesterol to vanquish number 1 killer
enGene (NASDAQ: ENGN) stock suffered an 83% plunge this past week that reflects just how competitive the field is among drug candidates for nonmuscle invasive bladder...
Nature Biotechnology, Published online: 11 May 2026; doi:10.1038/s41587-026-03155-8 While circRNA is often framed as a more stable, longer-lasting alternative to linear mRNA, its real-world advantages remain...
Proteolysis activity mapping and substrate discovery platform for identifying tumor-activated biosensors
For decades, physicians and scientists have thought that metformin, a biguanide drug that is prescribed for millions of people worldwide for type 2 diabetes (T2D), mainly...
Scientists at the University of Rochester pulled off a remarkable experiment: they transferred a longevity-related gene from the famously long-lived naked mole rat into mice, and...
A quantum tech firm that has collaborated with—and received investment from—Amgen is now planning to go public.Read More
NEW YORK — No quick dispatching of disease investigators. No televised news conference to inform the public. No timely health alerts to doctors. In the midst...
Below is a lightly edited, AI-generated transcript of the “First Opinion Podcast” interview with Will Flanary, aka Dr. Glaucomflecken. Be sure to sign up for the...